Ancient herbal mix put to the test against childhood eczema
NCT ID NCT05613062
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This pilot study tests whether a modified Chinese herbal formula, Modified Huang-Lian-Jie-Du Decoction (MHLJDD), can reduce eczema symptoms in children aged 4 to 17. Participants take either the herbal granules or a placebo twice daily for 12 weeks. The study measures changes in eczema severity using the EASI score.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a modified Chinese herbal formula called Modified Huang-Lian-Jie-Du Decoction (MHLJDD)
- What this could lead to
- If effective, this herbal formula could offer a new treatment option for children with eczema.
- What could go wrong
- This is a small early-stage pilot study with only 20 children, so results may not be conclusive. The herbal formula may cause allergic reactions or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
20 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Aug 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age of 4 to 17 (Chinese only); * With EASI ≥ 10; * Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematous papules and plaques; and * Provide a written informed consent form (signed by one of their parents) Exclusion Criteria: * History of allergy to Chinese medicines; * AD with Yang deficiency in syndrome differentiation, such as pale looking, always feeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such as urinary difficulty, excessive urination or incontinence * Known overt bacterial infections in the skin; * Known pregnancy; * Known severe medical conditions, such as cardiovascular, liver or renal dysfunction or Diabetes Mellitus; * Having used oral corticosteroids, oral antibiotics, other immunosuppressive or any preparation of oral herbal medicines for the treatment of AD in the past month; * Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitis or psoriasis; * Has taken anti-coagulant or anti-platelet drugs in the past month; * Has taken any probiotics, prebiotics in the last month; and * Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
School of Chinese Medicine
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin scans may predict who responds to dupilumab for eczema
- Can a daily liquid medicine calm severe eczema in toddlers and preschoolers?
- Scientists probe whether lebrikizumab rewires diseased skin at the molecular level
- Can a Lab-Made antibody calm severe eczema?
- Is your nose fueling infected eczema and scabies sores?
- Can an eczema drug reshape the Skin's microbial community?